2021年電影春節檔票房達逾75億人幣再創新高
據《新華社》報道, 全國電影票務綜合信息管理系統初步統計顯示,截至17日17時,2021年春節檔電影票房達75.44億元人民幣(下同),繼2019年59.05億元後,再次刷新春節檔全國電影票房,同時創造全球單一市場單日票房、全球單一市場周末票房等多項世界紀錄。
今年春節檔票房全部由國產影片貢獻。統計顯示,《你好,李煥英》、《唐人街探案3》兩部影片分別以25.67億元、34.81億元票房領跑明顯,佔據檔期總票房的80%。《刺殺小說家》以5.18億元、《熊出沒-狂野大陸》以3.64億元、《新神榜:哪吒重生》以2.28億元、《侍神令》以2.07億元、《人潮洶湧》以1.41億元跟隨其後。(ta/w) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.